News
GenSight Biologics Announces Publication Analyzing Visual Parameters of ND4-LHON Subjects Before LUMEVOQ® Treatment in Phase III Trials
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210908006154/en/
Figure 1. BCVA in untreated ND4-LHON patients as a
NANOBIOTIX Provides Business Update and Reports Financial Results for the First Half of 2021
Regulatory News:
NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities
Nanobiotix to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
Regulatory News:
NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities
UK MHRA Grants GenSight Biologics’ LUMEVOQ® Ophthalmic Gene Therapy Promising Innovative Medicine Designation
GenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal
Transgene Participates in New Cancer Research Consortium
Regulatory News:
Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, announces its participation in the launch of
GenSight Biologics Announces Publication of RESTORE Study Data Demonstrating Sustained Efficacy 3 Years After Unilateral Injection of LUMEVOQ®
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210830005575/en/
Figure 1. Evolution of best-corrected visual acuity
2021 HALF-YEAR BOIRON ACTIVITY
Cumulative Activity as of the end of june 2021
In thousands of euros 2020 2021 Variation at current exchange rates Variation at constant exchange rates France 104,930 126,32
Nanobiotix Provides Second Quarter Operational and Financial Update
Regulatory News:
NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’) (Paris:NANO) (NASDAQ:NBTX), a late-clinical stage biotechnology company pioneering physics-based approaches to
GenSight Biologics Announces Approval of the LUMEVOQ® Cohort Temporary Authorization for Use (ATUc) in France
Regulatory News:
GenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies
NANOBIOTIX Announces Initiation of New Clinical Study Evaluating NBTXR3 in Lung Cancer
Regulatory News:
NANOBIOTIX (Euronext : NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities
GenSight Biologics Reports Topline Results from REFLECT Phase III Clinical Trial, Confirming LUMEVOQ® Efficacy Including Better Efficacy with Bilateral Treatment
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210629006120/en/
Figure 1. Best-Corrected Visual Acuity (BCVA) Change
BOIRON : PROJECTED TIMETABLE OF THE NEXT PUBLICATIONS AND EVENTS 2022
The projected timetable of the next publications and events for the year 2022 is the following one:
Publications Date of publication (after market closing) Information meetings
First Head & Neck Cancer Patient Enrolled in the UK in a Phase I Trial with TG4050 (myvac® Platform), Transgene’s Innovative Individualized Immunotherapy
Regulatory News:
Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, today announces that the first UK patient has been
Transgene: First Patient Enrolled in Expanded Phase II Clinical Trial of TG4001 + Avelumab Vs Avelumab Alone in Patients With HPV16-positive Anogenital Cancers
Regulatory News:
Transgene (Paris:TNG) (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, today announces that a first patient has
GenSight Biologics Appoints Marion Ghibaudo as Chief Technical Officer to Lead GS030 Device Engineering
Regulatory News:
GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal
Transgene Strengthens Global IP Protection for its Novel Invir.IO™ Oncolytic Viruses Encoding Immune Checkpoint Inhibitors (ICIs)
Regulatory News:
Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today announces that the Japan Patent Office
NANOBIOTIX to Host Virtual KOL Event Discussing Potential First-in-Class Radioenhancer NBTXR3 In Immunotherapy on June 11, 2021
Regulatory News:
NANOBIOTIX (Paris:NANO) (NASDAQ:NBTX) (Euronext : NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to
NANOBIOTIX Announces the Appointment of Bart Van Rhijn as Chief Financial Officer and Member of the Executive Board to Support Global Expansion
Regulatory News:
NANOBIOTIX (Euronext : NANO – NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities
GenSight Biologics Announces Publication of Indirect Comparison Showing Treatment Effect of LUMEVOQ® versus Natural History in Frontiers in Neurology
Regulatory News:
GenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies
GenSight Biologics to Host a Key Opinion Leader Webinar on the Nature Medicine Case Report: Visual Recovery after GS030 Optogenetic Treatment
Regulatory News:
GenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies
Transgene and BioInvent Receive IND Approval from the U.S. FDA for BT-001, a Novel Oncolytic Virus for the Treatment of Solid Tumors
Regulatory News:
Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, and BioInvent International AB (“BioInvent”)
NANOBIOTIX to Participate in Fireside Chat at the Jefferies Virtual Healthcare Conference
Regulatory News:
NANOBIOTIX (Euronext : NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities
Transgene: Combined General Meeting of May 26, 2021
Regulatory News:
The Combined Ordinary and Extraordinary General Meeting of Transgene’s (Paris:TNG) shareholders was held today (May 26, 2021) at 10:00 a.m. at the Company's headquarters (400
Nanobiotix Announces the Appointment of Dr. Gary Phillips as Chairman of the Nanobiotix Supervisory Board
Regulatory News:
NANOBIOTIX (Euronext : NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities
CORRECTING and REPLACING Nanobiotix Announces Updated Results From Priority Pathways in Head and Neck Cancer and Immunotherapy for Potential First-in-class Radioenhancer NBTXR3 at 2021 Annual Meeting of the American Society for Clinical Oncology
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210519005957/en/
Please replace the release dated May 19, 2021 with